Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An eight- week randomized, double-blind, placebo-controlled, parallel group proof of concept study to assess the efficacy, safety and tolerability as well as the pharmacokinetic profile of oral solabegron (GW427353) 125mg and 50mg administered twice daily vs placebo in women with overactive bladder

Next Previous
X
Search
Trial Profile

An eight- week randomized, double-blind, placebo-controlled, parallel group proof of concept study to assess the efficacy, safety and tolerability as well as the pharmacokinetic profile of oral solabegron (GW427353) 125mg and 50mg administered twice daily vs placebo in women with overactive bladder

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Solabegron (Primary)
  • Indications Overactive bladder
  • Focus Proof of concept; Therapeutic Use
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 28 Feb 2012 Results presented at the 27th Congress of the European Association of Urology.
    • 25 Mar 2011 Positive top-line results reported in a AltheRx media release.
    • 18 Jan 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top